Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $179.1 million.

  • Allogene Therapeutics' Non-Current Assets fell 3710.96% to $179.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $828.7 million, marking a year-over-year decrease of 240.85%. This contributed to the annual value of $245.3 million for FY2024, which is 3353.0% up from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Non-Current Assets is $179.1 million, which was down 3710.96% from $187.9 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Non-Current Assets peaked at $579.5 million during Q4 2021, and registered a low of $179.1 million during Q3 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $270.9 million (2023), whereas its average is $324.7 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 15147.22% in 2021, then tumbled by 4948.19% in 2022.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Non-Current Assets stood at $579.5 million in 2021, then plummeted by 49.48% to $292.8 million in 2022, then plummeted by 37.24% to $183.7 million in 2023, then surged by 33.53% to $245.3 million in 2024, then fell by 27.01% to $179.1 million in 2025.
  • Its Non-Current Assets was $179.1 million in Q3 2025, compared to $187.9 million in Q2 2025 and $216.4 million in Q1 2025.